Understanding the recommendation Most patients with severe covid-19 would likely choose treatment with remdesivir given the potential reduction in time to clinical improvement. However, given the low certainty evidence for critical outcomes and the fact that different perspectives, values, and preferences...
Uses for RemdesivirCoronavirus Disease 2019 (COVID-19)Treatment of COVID-19 caused by SARS-CoV-2 in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5kg) who are hospitalized, or who are not hospitalized but have mild-to-moderate COVID-19, and are ...
2020年2月25日,美国国立卫生研究院(NIH)宣布,一项旨在评估Remdesivir治疗COVID-19 安全性和有效性的随机对照临床试验,已经在美国奥马哈的内布拉斯加大学医学中心(University of Nebraska Medical Center,UNMC)开始。此次试验的监管资助者是NIH下属的国家过敏和传染病研究所(the National Institute of Allergy and Infectiou...
新研究显示,抗病毒药物瑞德西韦(Remdesivir)可能有助于减轻长期新冠病毒(Long COVID)的相关症状。研究人员分析了HealthVerity数据库中的数据,涉及52,006名美国住院的COVID-19患者。这些患者在急性COVID-19疾病期间接受了瑞德西韦治疗,并评估了其对长期新冠病毒相关症状/诊断发生率的影响。 研究发现,与未接受瑞德西韦治...
WASHINGTON, May 1 (Xinhua) -- The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for an experimental anti-viral drug remdesivir to treat COVID-19, according to the agency on Friday. In an FDA fact sheet for patients and their families and caregivers...
4. Cao, B., et al.,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19.New England Journal of Medicine, 2020. 5. Grein, J., et al.,Compassionate Use of Remdesivir for Patients with Severe Covid-19.N Engl J Med, 2020....
自COVID-19疫情爆发以来,截止到2020年2月28日,全球已有52个国家和地区报告了COVID-19确诊病例,寻找潜在有效的治疗药物已成为全球疫情防控的当务之急,其中Remdesivir最受人们的关注。 此前,由首都医科大学作为申办方,中日友好医院曹彬教授牵头的中国Remdesivir治疗COVID-19的临床试验,已经于2020年2月5日在武汉金银潭...
吉利德:瑞德西韦依然对COVID-19有效 Gilead数据显示,remdesivir可降低高危新冠病毒患者的住院风险 最新数据显示,与安慰剂相比,Gilead Sciences(纳斯达克:GILD)的Remdisvir让高风险非住院患者的相关住院风险降低87%。 第二个终点是,与安慰剂相比,服用Remdisvir的患者在第28天因新冠病毒-19或全因死亡而就诊的风险降低了...
FDA Approves Veklury (remdesivir) for the Treatment of COVID-19 FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 22, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the ...
吉利德科学公司(GileadSciences)报告了其COVID-19治疗Veklury(remdesivir)的积极现实证据,表明所有因该病毒住院的患者的死亡率和再入院率均有所降低。 两项分析来自超过500,000名成年患者的临床实践信息的研究表明,在入院的头两天内开始使用Veklury与所有不同时间段内所有氧气水平的死亡率风险显着降低相关。